Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

Overview

The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).

Full Title of Study: “A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2019

Interventions

  • Drug: Clofarabine
    • Dose Escalation of Clofarabine
  • Drug: Mitoxantrone

Arms, Groups and Cohorts

  • Experimental: Mitoxantrone/Clofarabine
    • Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.

Clinical Trial Outcome Measures

Primary Measures

  • Determine MTD
    • Time Frame: 100 days
    • 2.1 To determine the maximal tolerated dose (MTD) and/or tolerable dose of escalating doses of clofarabine starting from 20mg/m2/day to 40mg/m2/day from Day 1 to Day 5 in combination with mitoxantrone 12mg/m2/day on Day 3-6 as reinduction therapy for children, adolescents and young adults with poor risk refractory/relapsed acute leukemia or high grade NHL.

Secondary Measures

  • Response Rate
    • Time Frame: 1 year
    • To determine the overall complete and partial response rate (OR) of the combination of mitoxantrone and clofarabine as reinduction therapy for children, adolescents and young adults with refractory/relapsed acute leukemia or high grade NHL.
  • Monitor for Minimal Residual Disease
    • Time Frame: 1 Year
    • To determine the percent of minimal residual disease (MRD) in the peripheral blood following reinduction with mitoxantrone and clofarabine reinduction therapy.

Participating in This Clinical Trial

Inclusion Criteria

Age ≤30.99 years old Disease Status (Part A – Safety Phase)

  • ALL in 1st, 2nd or 3rd relapse OR primary induction failure. – AML in 1st ,2nd or 3rd relapse OR primary induction failure. – T-or B — Lymphoblastic Lymphoma (T-LBL, B-LBL); Diffuse Large B-cell Lymphoma (DLBCL) or Burkitt Lymphoma/Leukemia in 1st, 2nd or 3rd relapse OR primary induction failure. 5.1.2.2 (Part B – Efficacy Phase) – ALL in 2nd or 3rd relapse OR primary induction failure. – AML in 2nd or 3rd relapse OR primary induction failure. – T-or B — Lymphoblastic Lymphoma (T-LBL, B-LBL); Diffuse Large B-cell Lymphoma (DLBCL) or Burkitt Lymphoma/Leukemia in 1st, 2nd or 3rd relapse OR primary induction failure. Adequate renal function defined as: – Normal Serum creatinine based on age or Creatinine clearance > 60 ml/min or >60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range. Adequate liver function defined as: – Direct bilirubin < 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) <3 x ULN Adequate cardiac function defined as: – Shortening fraction >27% by echocardiogram, or – Ejection fraction of >50% by radionuclide angiogram or echocardiogram. Performance Status – For patients age 1-16 years, Lansky score of ≥60. – For patients > 16 years, Karnofsky score of ≥60. Negative urine pregnancy test for females of child bearing age. Prior Therapy – Patients are eligible if they have been treated with clofarabine, mitoxantrone, or a combination of both in the past. However, the maximal lifetime cumulative previous anthracycline dose should not exceed doxorubicin dose equivalent of 450 mg/m2 (see Table 1). Patients who received more than one anthracycline prior to study entry should have each individual agent cumulative dose converted to doxorubicin equivalent and added together (eg, a patient who received cumulative dose of Daunorubicin at 200 mg/m2 and Mitoxantrone 48 mg/m2 has a total doxorubicin dose equivalent of 358.6 mg/m2 (200 mg/m2 x 0.833 + 48 mg/m2 x 4). Table 1. Anthracycline Conversion Agent Conversion Factor to Doxorubicin Dose Doxorubicin Multiply total dose x 1 Daunorubicin Multiply total dose x 0.833 Idarubicin Multiply total dose x 5 Mitoxantrone Multiply total dose x 4 Informed Consent – Patients or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of this protocol (including foreseeable risks and possible side effects), and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services. Exclusion Criteria:

Patients with prior myeloablative allogeneic stem cell transplantation <3 months prior to proposed enrollment on study and/or ≥Grade II active acute GVHD or extensive chronic GVHD. Females who are pregnant (positive HCG) or lactating. Karnofsky <60% or Lansky <60% if less than 16 years of age. Age >30.99 years of age. Patients with active CNS disease. Any patient with uncontrolled infection prior to study entry. Patients with Down syndrome are excluded.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • New York Medical College
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Mitchell Cairo, MD, 914-594-3650, mitchell_cairo@nymc.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.